ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis.
Beatriz Fernández-GómezMiguel A MarchenaDavid PiñeiroPaula Gómez-MartínEstefanía SánchezYolanda LaóGloria ValenciaSonia NoceraRocío Benítez-FernándezAna M Castaño-LeónAlfonso LagaresMacarena Hernández-JiménezFernando de CastroPublished in: British journal of pharmacology (2024)
Our findings reveal a new therapeutic approach for the treatment of inflammatory and demyelinating diseases such as MS. The molecular nature of the aptamer exerts not only an anti-inflammatory effect but also neuroprotective and remyelinating effects. The excellent safety profile demonstrated by ApTOLL in animals and humans opens the door to future clinical trials in MS patients.
Keyphrases
- multiple sclerosis
- clinical trial
- end stage renal disease
- mass spectrometry
- gold nanoparticles
- anti inflammatory
- ms ms
- ejection fraction
- newly diagnosed
- sensitive detection
- chronic kidney disease
- prognostic factors
- white matter
- peritoneal dialysis
- gene expression
- randomized controlled trial
- current status
- cerebral ischemia